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IntroDuCtIon
Patients diagnosed with cancer must be staged accurately prior 
to treatment decisions. In particular, it is imperative to detect 
metastatic disease, as this impacts considerably on therapeutic 
approach. Standard staging pathways are often complex, time 
consuming and involve several different imaging modalities, 
potentially adding to physical and psychological burden of 
patients with known or suspected cancer.1
Recent data suggest whole body MRI (WB-MRI) has 
potential as an “all-in-one” staging investigation that at 
least matches and possibly betters the accuracy of conven-
tional investigations for detecting metastatic disease.2,3 One 
critical but often neglected aspect influencing adoption 
of any new technology is patient experience. Low patient 
acceptability reduces adherence, which diminishes diag-
nostic impact, even when superior to existing tests. Uptake 
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objective: To evaluate perceived patient burden and 
acceptability of whole body MRI (WB-MRI) compared to 
standard staging investigations, and identify predictors 
of reduced tolerance.
Methods: Patients recruited to multicentre trials 
comparing WB-MRI with standard staging scans for 
lung and colorectal cancer were invited to complete two 
questionnaires: a baseline questionnaire at recruitment, 
measuring demographics, comorbidities, and distress; 
and a follow-up questionnaire after staging, measuring 
recovery time, comparative acceptability/satisfaction 
between WB-MRI and CT (colorectal cancer) and PET-CT 
(lung cancer), and perceived scan burden (scored 1, low; 
7, high). 
results: 115 patients (median age 66.3 years; 67 males) 
completed follow up and 103 baseline questionnaires. 69 
(63.9%) reported “immediate” recovery from WB-MRI 
and 73 (65.2%) judged it “very acceptable”. Perceived 
WB-MRI burden was greater than for CT (p  <  0.001) 
and PET-CT (p  <  0.001). High distress and comorbidi-
ties were associated with greater WB-MRI burden in 
adjusted analyses, with deprivation only approaching 
significance (adjusted regression β  = 0.223, p = 0.025; 
β = 0.191, p = 0.048; β = −0.186, p = 0.059 respectively). 
Age (p = 0.535), gender (p = 0.389), ethnicity (p = 0.081) 
and cancer type (p  =  0.201) were not predictive of 
WB-MRI burden.
Conclusion:  WB-MRI is marginally less acceptable and 
more burdensome than standard scans, particularly for 
patients with pre-existing distress and comorbidities. 
advances in knowledge: This research shows that 
WB-MRI scan burden, although low, is higher than 
for current staging modalities among patients with 
suspected colorectal or lung cancer. Psychological and 
physical comorbidities adversely impact on patient 
experience of WB-MRI. Patients with high distress 
or comorbid illness may need additional support to 
undergo a WB-MRI. 
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of bowel cancer screening colonoscopy is an example where 
perceived test burden impacts directly to reduce participation.4
WB-MRI has several attributes that can impact negatively on 
patient experience. Although protocols are dependent upon 
the underlying disease process, the scan acquisition time for 
cancer staging is typically around 45–60 min, and consider-
ably longer than CT or even PET-CT, with image acquisitions 
taking seconds or minutes respectively (although patient expe-
rience will be influenced by the total examination time, rather 
than just time taken for image acquisition). Moreover, MRI 
scanners are noisy and require full body and head immersion 
inside a relatively narrow “tube”, often necessitating closely 
applied receiver coils that restrict movement. Existing data 
show that 5–30% of patients experience distress both in antic-
ipation of MRI, and during the scan itself.5–7 Severe claustro-
phobia terminates scanning in 1–15%,8 and even if the patient 
completes the scan, distress precipitates motion artefacts 
that degrade image quality and impair diagnostic accuracy.9 
Furthermore, post-scan anxiety6 can engender MRI fear or 
phobia.10
Quantifying patient “distress” around diagnostic imaging is 
complex and has been expressed as procedural “burden”, a 
composite variable based on rating the level of physical and 
psychological discomfort related to scanning. Shortman et al11 
found the perceived burden of PET-MRI was greater than PET-CT; 
burden was related to scan preference with an overall prefer-
ence for PET-CT. A recent qualitative interview study reported 
that WB-MRI was perceived by some as more challenging than 
PET-CT and CT.12 To date, predictors of increased patient burden 
before or during WB-MRI have received little attention. Such 
knowledge may identify those who require additional psycholog-
ical support in advance or physical interventions such as sedation 
in order to complete scanning.13
The purpose of this study was to evaluate the perceived patient 
burden and acceptability of WB-MRI compared to standard 
staging investigations, and to identify predictors of  reduced 
patient tolerance.
MethoDs anD MaterIals
Participants
Patients recruited prospectively to two ongoing clinical trials, 
comparing the diagnostic accuracy and cost-effectiveness of 
WB-MRI with standard tests for staging colorectal and lung 
cancer, were invited to participate in the current study. Patients 
were eligible for the main trials if they were recently diagnosed 
or highly suspected of colorectal (Streamline C) or non-small 
cell lung cancer (Streamline L), such that they were referred for 
staging investigations. Written consent was obtained for partici-
pation in the current study. As part of the trial protocol, patients 
underwent WB-MRI staging in addition to all standard staging 
investigations such as CT and PET-CT. The full trial protocol 
details have been previously reported.14 The WB-MRI required 
intravenous cannulation for the administration of gadolinium. 
Full ethical permission was given by Camden and Islington 
National Research Ethics Service (NRES) on 03/10/2012, project 
numbers: 12/LO/1176 (Streamline C) and 12/LO/1177 (Stream-
line L).
Between March 2013 and July 2015, 392 consecutive patients 
recruited to the main trials were given the option to participate 
in either an interview study (reported elsewhere)12 or the current 
questionnaire study as part of the informed consent process for 
the main trials. 350 (89.3%) consented. The interview study 
investigated patients’ experiences of staging investigations.
Initially, patients (n = 91) were recruited to the interview study, 
previously reported.12 Thereafter, patients were recruited exclu-
sively to the questionnaire study presented here. None of the 
patients who took part in the present study took part in the prior 
interview study.
The full recruitment pathway and reasons for exclusion is 
presented in Figure  1. A total of 115 patients completing the 
follow up questionnaires (see below) were included in the 
analyses.
Procedures
Patients were asked to complete two questionnaires. The first 
(baseline) questionnaire was mailed to patients within 2 days of 
being registered for the Streamline trials, completed around the 
time patients were undergoing their staging investigations, and 
returned using a stamped addressed reply envelope. A second 
“post-staging” questionnaire was posted 1 month after the base-
line questionnaire was administered and was completed after all 
staging investigations were completed. Patients were paid £20 
for participation, which was continued until a minimum of 100 
patients had returned both questionnaires (50 for Streamline L 
and 50 for Streamline C)—see power calculation below.
Questionnaire content
The following data were collected in the baseline questionnaire:
(1) Emotional distress: the 12-item General Health Questionnaire 
(GHQ-12)15 was used to assess psychological distress. An 
example item is, “In the last three months have you….been 
able to concentrate on whatever you’re doing”. Using the 
GHQ-12 binary coding method (0,0,1,1), a mean sum score 
(if at least 50% of items were answered) was created ranging 
from 0 to 12. A score of 4 or higher is considered indicative 
of significant distress levels.16
(2) Comorbidity: patients were asked about their current and 
recent physical health and mental well-being. Patients were 
asked to report (“yes” or “no”) whether they had any of 
the following diseases: heart or vascular disease, diabetes, 
epilepsy, stroke, arthritis, asthma, mental or emotional 
disorder. There was also an option to provide details of 
other illness. A response of “yes” to any illness was coded 
and a dichotomous “comorbidity” variable was created, 
whereby the presence of one or more comorbid illness 
was reported: either yes or no. The presence of a mental 
or emotional disorder was excluded as this was captured 
in the GHQ-12. Self-report measures of comorbidity 
have been shown to be valid17,18 and offer a more cost- 
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effective method of data collection than medical record-
based measures.
(3) Demographics: patients were asked their age, gender and 
ethnicity. Missing demographic data on age and gender as well 
as zip code data were supplied via the central trial database 
(with patient consent). Zip code data were used to calculate 
an area based deprivation score for each individual using the 
2010 Index of Multiple Deprivation scale,19 categorised into 
quintiles from 1 (highest levels of deprivation) to 5 (lowest).
Part of the follow-up questionnaire asked patients about their 
comparative experience of WB-MRI and staging CT chest, 
abdomen and pelvis (standard scan) if recruited to Streamline 
C, or to PET-CT (standard scan) if recruited to Streamline L. The 
following data were captured.
(1) Scan recovery, satisfaction and acceptability: patients 
rated their post-scan recovery on a 9-point scale ranging 
from “immediate” to “a week”. Data were collapsed into 
three categories “immediate”, “up to 30 min” and “over 
30 min” for analysis. Patients also rated how satisfied 
they were with the information received before scanning, 
communication and departmental facilities, as well as 
the overall acceptability of scans, on a scale of 1  (very 
dissatisfied/ not at all acceptable) to 4 (very satisfied/ very 
acceptable).
Figure 1. Flow diagram of participants through the study (March 2013–July 2015).
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(2) Scan burden was quantified using a questionnaire adapted 
from one previously used to assess acceptability of 
colonoscopy20,21 (Supplementary material 1a, Supplementary 
material available online). Patients completed the 26-item 
scale for both WB-MRI and standard scans, describing 
their experiences by ticking agreement on a 1–7 Likert 
scale, where 1 and 7 were anchored to bipolar statements 
related to scan discomfort (13 items), worry (6 items), and 
satisfaction (7 items). An example discomfort item was 
1= “not claustrophobic” to 7= “claustrophobic”. Subscores 
for discomfort, worry and satisfaction scales were computed 
from the mean of completed items (if less than 50% of items 
were completed, the response was coded as missing). A total 
score “scan burden” was computed by taking the mean of 
discomfort, worry and reverse scored satisfaction subscales 
with higher scores equating to greater scan burden.
Power calculation
Power (G*Power-v. 3)22 was based on rejecting the null hypoth-
esis that there was no significant difference in perceived burden 
of WB-MRI when compared to standard staging (related t-test). 
Assuming a medium effect size (d = 0.5), α of 0.05 and 95% 
power,23 a minimum number of 90 patients were required across 
the two study cohorts (45 in Streamline C and 45 in Streamline L). 
An effect size of 0.5 is considered the minimal important difference 
in quality of life measures,24 where minimal important difference 
is defined as the smallest difference that patients view as important 
(beneficial or harmful), and would result in a doctor considering a 
change in the patient’s management.25
Statistical analysis
Analysis was performed using SPSS v. 22. Differences in demo-
graphic and psychological characteristics between Streamline 
L and Streamline C cohorts were assessed using the Mann–
Whitney U test, and X2 or Fisher’s Exact tests (if 20% or more 
of the cells in the contingency table had expected counts of less 
than 5) as appropriate. Related samples Wilcoxon sign tests were 
used to assess differences between WB-MRI  vs  CT/PET-CT 
in terms of scan recovery time, scan acceptability, and satisfac-
tion with scan-related information, facilities, communication 
and scan burden. Linear regression tested the predictive value 
for WB-MRI scan burden of data collected in the baseline ques-
tionnaire. Individual predictors were entered in unadjusted anal-
yses and those items achieving statistical significance were then 
entered into a multivariate analysis. Statistical significance was 
assigned at the 5% level, two-tailed.
results
Of the 350 patients agreeing to participate in the questionnaire 
or separate interview study, rates of consent were significantly 
higher among patients recruited to Streamline L compared 
to those recruited to Streamline C; (93.1 vs 85.8%; X2 = 5.451, 
df = 1; p = 0.020, Figure 1). There were no differences in basic 
demographics between those who consented compared to those 
who did not (Supplementary material 1b).
In total, 214 patients were sent both questionnaires of whom 99 
were excluded leaving 115 for analysis. Reasons for exclusion 
were non-response (n = 71), returned baseline questionnaire only 
(n = 27), and trial withdrawal (n = 1) (Figure 1). Patients with lower 
levels of deprivation were more likely to return the post-staging 
questionnaire (linear X2 = 7.113, df = 1; p = 0.008). There were no 
differences in sex (p = 0.059), age (p = 0.676) or cancer type (X2 = 
0.442; df = 1; p = 0.506), between those who did, and did not return 
the post staging questionnaire (Supplementary material 1c).
Full demographics of the 115 patients are shown in Table  1. 
Overall, 103 patients (median age 66; 58 males) completed both 
questionnaires and 12 (median age 60; 9 males) completed the 
post-staging questionnaire only. 61 patients were recruited to 
Streamline C and 54 to Streamline L. Female patients recruited 
to Streamline C (n = 24) were significantly younger than those 
recruited to Streamline L (n = 24) (median age 60 vs 73 years; 
p = 0.003), with no significant age difference between males 
(66 years, n = 37 vs  66 years, n = 30, respectively; p = 0.480).
Patients recruited to Streamline L were significantly more likely 
to report additional comorbidity than those recruited to Stream-
line C (66.7 vs 40.4%, p = 0.008) with no significant differences 
for the presence of baseline psychological distress between the 
two trial cohorts (Table 1).
Post-scan patient recovery and scan acceptability
Patients’ responses to scan recovery time and overall acceptability 
are summarised in Table 2. There were no significant differences in 
recovery time after WB-MRI compared to CT/PET CT, with 63.9% 
of patients who completed this item (n = 69) reporting “immediate” 
recovery following WB-MRI compared with 65.1% following CT/
PET-CT (Table 2). However, scan acceptability ratings were signifi-
cantly lower for WB-MRI compared to both CT and PET-CT. 
Patients’ satisfaction with information before the scan and facilities, 
together with communication during the scan and were all high 
and not significantly different between WB-MRI and either CT or 
PET-CT (Table 2).
Scan burden
In general, patients tolerated all the imaging modalities well and 
reported low levels of scan burden. Mean ratings for scan discom-
fort and worry ranged from 1.63 to 2.65, where 7 represents 
maximum discomfort or worry. Mean satisfaction scores ranged 
from 6.25 to 6.53, where 7 represents maximum satisfaction.
However, mean burden scores for WB-MRI were significantly 
greater than those of PET-CT and CT (Table  3). The higher 
burden of WB-MRI was mainly due to items related to “discom-
fort”, although there were also significant differences in relation to 
“satisfaction”. Questionnaire items related to “worry” were only less 
favourable for WB-MRI in comparison to CT, and did not differ 
for WB-MRI in comparison to PET-CT. Specific items within the 
discomfort subscale particularly relevant to WB-MRI, showed 
WB-MRI conferred significantly greater feelings of claustrophobia 
than both CT (means scores 2.81 vs 1.51; p < 0.001) and PET-CT 
(mean scores 3.04 vs 1.98; p < 0.001); greater burden from scan-re-
lated noise compared with both CT (means 2.84 vs 1.73; p < 0.001) 
and PET-CT (2.85 vs 1.63; p < 0.001). In general, the intravenous 
injections required for each of the three scan types resulted in 
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low levels of discomfort which did not differ between scan type 
(WB-MRI  vs  CT: 1.59 vs 1.56, p = 0.637; WB-MRI  vs  PET-CT: 
1.86 vs 1.73, p = 0.225).
WB-MRI burden was not rated differently between those 
recruited to Streamline C or Streamline L cohorts (see below). 
In contrast, patients recruited to Streamline L reported signifi-
cantly more worry and discomfort during PET-CT compared to 
the equivalent ratings for CT by those recruited to Streamline C; 
(worry 2.52 vs 2.00; p < 0.001; discomfort 2.04 vs 1.63: p < 0.001).
Predictors of WB-MRI scan burden
The regression analysis for predictors of WB-MRI scan burden 
showed that the presence of comorbidity, psychological distress 
and deprivation were significant predictors in unadjusted anal-
ysis (β = 0.242, p = 0.015, β = 0.305, p = 0.002 and β = −0.265, 
p = 0.005 respectively), with age, gender, and cancer type non-sig-
nificant predictors and ethnicity approaching significance 
(β = 0.059, p = 0.535; β = 0.083, p = 0.389; β = −0.122, p = 0.201; 
β = −0.179, p = 0.081). In the adjusted analyses, only psycho-
logical distress and presence of comorbidities remained signifi-
cantly predictive (β = 0.223; p = 0.025; β = 0.191, p = 0.048) with 
deprivation approaching significance (β = −0.186, p = 0.059).
DIsCussIon
As data supporting WB-MRI for cancer staging accumulates2,3 
and the technology enters clinical practice, it is important to 
understand patient experience and overall acceptability. Cancer 
patients are vulnerable and may already be suffering significant 
distress1,26 which may impact on the acceptability of potentially 
unpleasant staging investigations.
We investigated patient experience and overall acceptability of 
WB-MRI compared to standard PET-CT and CT in two cohorts 
of patients recently diagnosed or highly suspected of lung or 
colorectal cancer. While standard scans can distress patients,27,28 
we hypothesised that patients would find WB-MRI less accept-
able given its attributes. This hypothesis was informed by related 
qualitative work that indicated some (but not all) patients found 
the scan a challenge and comparatively more so than CT and 
PET-CT scans.12
In reality, our data show that, in general, patients tolerate 
WB-MRI well; absolute discomfort and worry were low, and 
satisfaction was high. However, the burden of WB-MRI was 
significantly greater than for both PET-CT and CT. This differ-
ential was particularly apparent when compared to CT, the stan-
dard first-line staging investigation for patients with colorectal 
cancer. We also found evidence that PET-CT burden was greater 
than for CT, particularly for items pertaining to discomfort and 
worry, although, as noted below, the higher prevalence of comor-
bidities in the lung cancer patient cohort may have influenced 
their tolerance of PET-CT.
Although our findings are perhaps intuitive given the known 
attributes of the tests, they are actually at odds with the findings 
Table 1. Demographic and psychological characteristics of participants who completed the post-staging questionnaire
Overall Patient cohort Differences between patient 
cohorts
N = 115 La n = 54 Cb n = 61
Demographic characteristics
  Agec [median in years (range)] 66.3 (31–89) 69.7 (50–89) 64.2 (31–85) Mann–Whitney U test p = 0.010
  Male genderc 58.3 (67) 55.6 (30) 60.7 (37) X2 = 0.306; df = 1; p = 0.580
  White ethnicityd 91.8 (90) 93.8 (45) 90.0 (45) Fisher’s Exact; p = 0.715
IMD deprivationc 
  1 (highest) 23.5 (27) 25.9 (14) 21.3 (13)
X2 = 0.3875; df = 4; p = 0.423
  2 24.3 (28) 27.8 (15) 21.3 (13)
  3 21.7 (25) 24.1 (13) 19.7 (12)
  4 17.4 (20) 14.8 (8) 19.7 (12)
  5 (lowest) 13.0 (15) 7.4 (4) 18.0 (11)
Physical and emotional well-being
  Comorbidity (at least one comorbid illness reported)d 53.4 (55) 66.7 (34) 40.4 (21) X2 = 7.147; df = 1; p = 0.008
Emotional distressd    
  (GHQ-12 score of 4 or higher) 41.6 (42) 47.1 (24) 36.0 (18) X2 = 1.271; df = 1; p = 0.260
GHQ-12, 12-Item General Health Questionnaire; IMD, Index of Multiple Deprivation.
Numbers are percent (n) unless otherwise specified.
aNon-small cell lung cancer.
bColorectal cancer % is valid percent where there is missing data.
cNo missing data.
dMissing data greater than 5%.
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Table 2. Comparative experience of WB-MRI  vs  CT/PET-CT
Overall Lung (L)a Colorectal (C)b Group differences (Wilcoxon sign test)
Recovery time    
WB-MRIc  
p = 0.465d
p = 0.735e     
  Immediate 63.9 (69) 61.5 (32)d 66.1 (37)e 
  Up to 30 min 25.9 (28) 23.1 (12) 28.6 (16)
  Over 30 min 10.2 (11) 15.4 (8) 5.4 (3)
CT/PET-CTc  
  Immediate 65.1 (69) 58.8 (30)d 70.9 (39)e 
  Up to 30 min 21.7 (23) 23.5 (12) 20.0 (11)
  Over 30 min 13.2 (14) 17.6 (9) 9.1 (5)
Acceptability
WB-MRIc   
p = 0.035d
p = 0.005e     
  Very 65.2 (73) 64.8 (35)d 65.5 (38)e 
  Fairly 30.4 (34) 29.6 (16) 31.0 (18)
  Slightly 3.6 (4) 3.7 (2) 3.4 (2)
  Not at all 0.9 (1) 1.9 (1) 0.0 (0)
CT/PET-CTc  
  Very 77.8 (84) 75.0 (39)d 80.4 (45)e 
  Fairly 21.3 (23) 23.1 (12) 19.6 (11)
  Slightly 0.0 (0) 0.0 (0) 0.0 (0)
  Not at all 0.9 (1) 1.9 (1) 0.0 (0)
Satisfied with information received before scan  
WB-MRIc
p = 0.169d
p = 0.071e     
  Very satisfied 55.6 (60) 51.9 (27)d 58.9 (33)e 
  Satisfied 37.0 (40) 40.4 (21) 33.9 (19)
  Dissatisfied 3.7 (4) 5.8 (3) 1.8 (1)
  Very dissatisfied 3.7 (4) 1.9 (1) 5.4 (3)
CT/PET-CTc
  Very satisfied 57.5 (61) 49.0 (25)d 65.5 (36)e 
  Satisfied 34.9 (37) 37.3 (19) 32.7 (18)
  Dissatisfied 0.9 (1) 2.0 (1) 0 (0)
  Very dissatisfied 6.6 (7) 11.8 (6) 1.8 (1)
Satisfied with communication during scan  
WB-MRIc
p = 0.637d
p = 0.059e       Very satisfied 56.1 (60) 57.7 (30)
d 54.5 (30)e 
  Satisfied 39.3 (42) 34.6 (18) 43.6 (24)
  Dissatisfied 2.8 (3) 5.8 (3) 0 (0)
  Very dissatisfied 1.9 (2) 1.9 (1) 1.8 (1)
CT/PET-CTc
  Very satisfied 64.2 (68) 62.7 (32)d 65.5 (36)e 
  Satisfied 32.1 (34) 31.4 (16) 32.7 (18)
  Dissatisfied 1.9 (2) 3.9 (2) 0 (0)
  Very dissatisfied 1.9 (2) 2.0 (1) 1.8 (1)
(Continued)
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of Adams et al29 who compared WB-MRI with CT in patients 
undergoing lymphoma staging. Adams found that patients found 
WB-MRI more “friendly”, less unpleasant, and less “worrisome” 
than CT, attributing the relative negative evaluation of CT to 
more invasive preparation—patients had an intravenous line 
placed and consumed oral contrast. In our study, mean patient 
age (65 years) was considerably higher than the 50 years reported 
by Adams et al furthermore, the Streamline trial WB-MRI 
protocols required IV gadolinium, which may also help explain 
discrepant findings.
We investigated factors that might predict worsened scan 
experience. As would perhaps be expected in a cohort of 
patients undergoing investigations for suspected or newly 
Overall Lung (L)a Colorectal (C)b Group differences (Wilcoxon sign test)
Satisfaction with facilities  
WB-MRIc
p = 0.225d
p = 0.480e     
  Very satisfied 45.8 (49) 49.0 (25)d 42.9 (24)e 
  Satisfied 45.8 (49) 43.1 (22) 48.2 (27)
  Dissatisfied 4.7 (5) 2.0 (1) 7.1 (4)
  Very dissatisfied 3.7 (4) 5.9 (3) 1.8 (1)
CT/PET-CTc
  Very satisfied 54.7 (58) 62.7 (32)d 47.3 (26)e 
  Satisfied 38.7 (41) 33.3 (17) 43.6 (24)
  Dissatisfied 4.7 (5) 2.0 (1) 7.3 (4)
  Very dissatisfied 1.9 (2) 2.0 (1) 1.8 (1)
WB-MRI, whole body MRI.
Numbers are percent (n).
aNon-small cell lung cancer, WB-MRI vs PET-CT.
bColorectal cancer, WB-MRI vs CT.
cMissing data greater than 5%. % is valid percent.
dComparison between WB-MRI and PET-CT (Lung).
e Comparison between WB-MRI and CT (Colorectal).
Table 2. (Continued)
Table 3. Comparative scan burden (WB-MRI  vs  CT/PET-CT)
Overall La cohort Cb cohort Group differences using Wilcoxon signed-rank test
Total patient burden (scores 1–7)
  WB-MRIc  2.21 (1.1) 2.33d (0.94) 2.09e (1.18) p < 0.001d
  CT/PET-CTc 1.87 (0.98) 2.05d (0.82) 1.70e (1.1) p < 0.001e
Discomfort sub-scale (1–7)
  WB-MRIc 2.51 (1.26) 2.65d (1.14) 2.30e (1.22) p < 0.001d
  CT/PET-CTc 1.83 (1.05) 2.04d (.90) 1.63e (1.15) p < 0.001e
Worry subscale (1–7)
  WB-MRIc 2.47 (1.32) 2.62d (1.15) 2.23e (1.31) p = 0.208d
  CT/PET-CTc 2.24 (1.23) 2.52d (1.15) 2.00e (1.28) p = 0.041e
Satisfaction subscale (1–7)
  WB-MRIc 6.25 (1.06) 6.27d (0.85) 6.26e (1.23) p = 0.036d
  CT/PET-CTc 6.49f (0.89) 6.43d (0.76) 6.53e (1.01) p < 0.001e
WB-MRI, whole body MRI.
Numbers are mean (SD).
aNon-small cell lung cancer, WB-MRI vs PET-CT.
bColorectal cancer, WB-MRI vs CT.
cMissing data greater than 5%.
dComparison between WB-MRI and PET-CT (Lung).
eComparison between WB-MRI and CT (Colorectal).
8 of 10 birpublications.org/bjr Br J Radiol;91:20170731
BJR  Evans et al
diagnosed cancer, a significant proportion reported high 
level of baseline distress, and this distress was associated with 
subsequent higher WB-MRI burden. Furthermore, patients 
with additional comorbidity experienced greater burden. A 
recent review suggests that comorbidities can reduce cancer 
survival and comorbidity is associated with receiving subop-
timal treatment.30 Our data suggest comorbidity influences 
the tolerability of WB-MRI, which may impact on scan quality 
and diagnostic accuracy. Further exploration of how comor-
bidity influences patients' experience of cancer staging and 
treatment is, therefore, important to maximise survival. High 
deprivation was associated with increased WB-MRI burden in 
the unadjusted analysis. Deprivation is associated with higher 
cancer incidence and mortality, particularly for lung cancer,31 
in addition to decreased engagement with cancer screening 
programmes.32 Further work to understand how deprivation 
influences perceived burden is important to improve experi-
ence and engagement.
Our study does have limitations. Patients recruited to the 
Streamline trials volunteered to take part in our question-
naire study. The proportion of patients who completed the 
scan experience questions was arguably quite low at 54%. 
However, this is in line with postal survey completion rates 
observed in other similar studies.33 We did consider issuing 
reminders to patients to increase response rate, but decided 
against this so as to not increase patient burden at a difficult 
time: patients had to complete and return two questionnaires 
within 1 month of a new cancer diagnosis. Although those 
who took part seem representative of Streamline trial partic-
ipants overall (judged by our comparisons of registered and 
recruited patients), our sample may not represent all patients 
who may undergo WB-MRI in daily clinical practice. Patients 
in our study were relatively young compared to the typical age 
of diagnosis with lung or colorectal cancer and it is possible 
that scan acceptability is greater in younger patients. However, 
the study was done within the context of a large multi-institu-
tion study of WB-MRI, and the results are very likely to repre-
sentative of most National Health Service institutions. The 
study was powered to detect clinically meaningful differences 
in perceptions of burden generated by WB-MRI and standard 
scans, while the power calculation prior to the start of the 
study assumed we would be using paired samples t-tests rather 
than Wilcoxon signed-rank tests, significant differences were 
still detected with the latter. Other studies have used much 
larger numbers to try and predict poor tolerance of MRI.8 It is 
possible our null findings for some predictors (e.g. age, gender 
and cancer type) and findings of borderline significance for the 
role of deprivation in adjusted analyses, may be due to lack of 
statistical power to detect small effects. Patients were asked to 
complete the baseline questionnaire at the point of trial regis-
tration, with the post-staging questionnaire 1 month later. 
Scan timing meant that at baseline some patients had already 
completed WB-MRI by the time they completed the baseline 
questionnaire and a whole month had elapsed before they 
were asked to answer the post-scan evaluation questions. This 
may have introduced some recall bias into their responses. 
However, recalled experience some time after the event may 
have greater prediction for future health behaviours than 
immediate recollection.34 Some patients may have been aware 
of their diagnosis at the time of completing the baseline ques-
tionnaire, when distress levels were assessed. We did not ask 
people whether or not they knew their diagnosis at baseline, 
but rates of distress among people undergoing investigations 
for suspected cancer are similar to those among people with 
a confirmed diagnosis, so this is unlikely to have affected the 
results observed.1
It would have been useful to quantify patient comorbidity with 
scores such as the Charlson score.35 However, such scores are 
time-consuming and collection of complete and clean data 
were not possible with our resources. As noted in the methods, 
however, self-report measures of comorbidity have been shown 
to be valid17,18 and offer a more cost-effective method of data 
collection than medical record-based measures.
A further limitation is that our study focused on scan experi-
ence, and although a number of questions were asked about scan 
acceptability, recovery time, and satisfaction with information, 
communication and facilities we did not examine patient views 
about overall appointment time, or how they viewed the time 
in the scanner  vs  the time waiting before and after the scan. 
However of note, satisfaction was very high for all these items, 
and did not differ between scans.
ConClusIons
In conclusion, patients undergoing staging for lung or colorectal 
cancer found WB-MRI more burdensome than standard CT and 
PET-CT, although absolute differences in burden scores were 
small; most patients found WB-MRI fairly or very acceptable. 
Our findings demonstrate that patients with medical comorbid-
ities, or with pre-existing high levels of psychological distress, 
tolerate WB-MRI less well, and may, therefore, benefit from 
additional support.
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